Gastrointestinal Safety of an Extended-Release, Nondeformable, Oral Dosage Form (OROS??)*
about
Evolution of stimulants to treat ADHD: transdermal methylphenidateAn overview of clinical and commercial impact of drug delivery systemsPharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone.A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain.An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain.Curse of the ghost pills: the role of oral controlled-release formulations in the passage of empty intact shells in faeces. Two case reports and a literature review relevant to psychiatry.The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia.Paliperidone-ER: first atypical antipsychotic with oral extended release formulation.Once-Daily OROS Hydromorphone for Management of Cancer Pain: an Open-Label, Multi-Center, Non-Interventional Study.Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.The pharmacokinetics of a long-acting OROS hydromorphone formulation.Impact of dose frequency on compliance and health outcomes: a literature review (1966-2006).Pharmacobezoars described and demystified.Controlled release drug delivery systems to improve post-operative pharmacotherapy.Hydromorphone for cancer pain.Efficacy of the sustained-release hydromorphone in neuropathic pain management: pooled analysis of three open-label studies.Oral delivery of biologics using drug-device combinations.Pharmacobezoar in an obese patient with intragastric balloon: a case revealed at endoscopy.A randomized study of the effects of food on the pharmacokinetics of once-daily extended-release hydromorphone in healthy volunteers.
P2860
Q22252903-858E9166-B695-4DCC-B568-269808D16E4FQ27007143-6E170DF8-D142-4893-9859-10B722D34CEAQ33271475-82F1B9C0-FBE3-4BF3-8776-F88C10228FA3Q33381853-0CDA3820-7EEE-4101-A5D5-D723B0CE9CA4Q33503399-77F0D96B-8EA6-465D-AC24-31ACFBCE8EDAQ33949355-5712ED5B-571A-4997-9D32-B97AA1F2FE22Q36984231-19B262C2-DEE2-427B-8B3E-A8E73C6B20CEQ37083634-1B7A1529-1F12-4095-9E4C-2F48A56F167FQ37404917-3CC03EB3-D8E9-4679-B712-A4CE25EED571Q37422493-DAA2FEDD-7DC2-43AE-A8F5-40F589E7E117Q37644498-08684D6E-2F48-4E86-8A5E-B0F1F5E4216DQ37763151-316A88E5-6D26-4837-A588-BDD109005DE4Q37849300-A0CAA89D-DB01-4615-A454-37C7CD95D65AQ38850096-C8EF582D-3F5C-4657-9525-E011275EF385Q38977999-AD2338FC-230C-4623-8480-F26535985E31Q39281251-F1E035FD-EFDF-4A27-A0B0-C6BBB1A18CCCQ47830247-0140F13C-A87F-4F80-A452-DE64DBAA8A6DQ48604362-8D3D7F2B-1F4F-4ED7-BDC3-63B81D89E21DQ51386305-B353464A-E743-4F9C-96AC-9F5C23E4074A
P2860
Gastrointestinal Safety of an Extended-Release, Nondeformable, Oral Dosage Form (OROS??)*
description
2002 nî lūn-bûn
@nan
2002 թուականին հրատարակուած գիտական յօդուած
@hyw
2002 թվականին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Gastrointestinal Safety of an Extended-Release, Nondeformable, Oral Dosage Form (OROS??)*
@ast
Gastrointestinal Safety of an Extended-Release, Nondeformable, Oral Dosage Form (OROS??)*
@en
type
label
Gastrointestinal Safety of an Extended-Release, Nondeformable, Oral Dosage Form (OROS??)*
@ast
Gastrointestinal Safety of an Extended-Release, Nondeformable, Oral Dosage Form (OROS??)*
@en
prefLabel
Gastrointestinal Safety of an Extended-Release, Nondeformable, Oral Dosage Form (OROS??)*
@ast
Gastrointestinal Safety of an Extended-Release, Nondeformable, Oral Dosage Form (OROS??)*
@en
P2093
P3181
P1433
P1476
Gastrointestinal Safety of an Extended-Release, Nondeformable, Oral Dosage Form (OROS??)*
@en
P2093
Deborah S. Waxman
Dorsey M. Bass
Mary Prevo
P304
P3181
P356
10.2165/00002018-200225140-00004
P577
2002-01-01T00:00:00Z
P6179
1040190623